Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genotonorm in Children with Growth Retardation due to Corticotherapy
NCT00163189Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jan 2005
- Primary completion
- Dec 2014
- Modality
- Hormone, rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of somatropin in growth hormone deficiency (GHD), sponsored by Pfizer. Primary endpoint: Change From Baseline in Height Standard Deviation Score (SDS) for Chronological Age (CA) at 36 months. Started Jan 2005; status: completed.
02
Drugs
somatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT00163189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00163189.